Cornerstone Capital Inc. Invests $24.57 Million in Thermo Fisher Scientific Inc. $TMO

Key Points

• Cornerstone Capital purchased 49,009 shares of Thermo Fisher Scientific worth approximately $24.57 million, making TMO its 19th-largest holding and representing about 2.2% of its portfolio. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly EPS of $6.03 and revenue of $11.99 billion, exceeding analyst expectations; revenue increased 10.5% year over year. The company provided fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $619.41 price target. The company also declared a quarterly dividend of $0.47 per share, while insiders have sold 52,053 shares worth $30.64 million over the past three months.

Cornerstone Capital Inc. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 49,009 shares of the medical research company's stock, valued at approximately $24,571,000. Thermo Fisher Scientific makes up approximately 2.2% of Cornerstone Capital Inc.'s investment portfolio, making the stock its 19th biggest holding.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Salomon & Ludwin LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,095 shares of the medical research company's stock valued at $669,000 after buying an additional 17 shares in the last quarter. Elyxium Wealth LLC raised its stake in Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company's stock worth $613,000 after acquiring an additional 20 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. boosted its stake in Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company's stock valued at $1,436,000 after acquiring an additional 20 shares in the last quarter. Finally, Confluence Wealth Services Inc. grew its holdings in shares of Thermo Fisher Scientific by 0.5% during the fourth quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company's stock worth $2,487,000 after purchasing an additional 22 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 0.0%

Thermo Fisher Scientific stock opened at $588.17 on Monday. The stock has a 50 day moving average of $529.37 and a two-hundred day moving average of $508.75. Thermo Fisher Scientific Inc. has a twelve month low of $435.27 and a twelve month high of $643.99. The stock has a market capitalization of $217.48 billion, a price-to-earnings ratio of 31.64, a PEG ratio of 2.39 and a beta of 0.84. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter in the previous year, the company posted $4.28 earnings per share. The company's revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Analyst Ratings Changes

Several research firms have recently weighed in on TMO. Morgan Stanley boosted their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Piper Sandler lifted their price target on Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a "neutral" rating in a research report on Monday, July 27th. KeyCorp reissued an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Insider Buying and Selling

In other news, VP Lisa P. Britt sold 5,850 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the completion of the sale, the vice president owned 14,784 shares in the company, valued at approximately $8,574,720. This trade represents a 28.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Gianluca Pettiti sold 400 shares of the business's stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $565.00, for a total transaction of $226,000.00. Following the transaction, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source